(Q38124060)

29 August 2017

title

Combination of adjuvants: the future of vaccine design (English)

1 reference

29 August 2017

1 reference

Adele Mount

1

1 reference

29 August 2017

Sandra Koernig

2

1 reference

29 August 2017

Anabel Silva

3

1 reference

29 August 2017

Debbie Drane

4

1 reference

29 August 2017

Eugene Maraskovsky

5

1 reference

29 August 2017

Adriana Baz Morelli

6

1 reference

29 August 2017

publication date

1 July 2013

1 reference

Expert Review of Vaccines

29 August 2017

published in

1 reference

29 August 2017

volume

12

1 reference

29 August 2017

issue

7

1 reference

29 August 2017

page(s)

733-746

1 reference

Unmet needs in modern vaccinology: adjuvants to improve the immune response

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Patented cancer vaccines: the promising leads

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Hepatitis A and hepatitis C viruses: divergent infection outcomes marked by similarities in induction and evasion of interferon responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

HIV-1, interferon and the interferon regulatory factor system: an interplay between induction, antiviral responses and viral evasion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Mycobacterium tuberculosis controls microRNA-99b (miR-99b) expression in infected murine dendritic cells to modulate host immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Mycobacterium tuberculosis inhibits neutrophil apoptosis, leading to delayed activation of naive CD4 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Mycobacterium tuberculosis directs immunofocusing of CD8+ T cell responses despite vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Towards an understanding of the adjuvant action of aluminium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Influenza vaccines: what do we want and how can we get it?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

The history of MF59(®) adjuvant: a phoenix that arose from the ashes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Epaxal: a virosomal vaccine to prevent hepatitis A infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

New hepatitis B vaccine formulated with an improved adjuvant system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Vaccine adjuvants: putting innate immunity to work

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Programming the magnitude and persistence of antibody responses with innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Vaccine adjuvants: a priority for vaccine research

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Pattern recognition receptors and control of adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Innate immunity--cross-talk with adaptive immunity through pattern recognition receptors and cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

TLR-based immune adjuvants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Combination adjuvants: the next generation of adjuvants?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Modulating immunity as a therapy for bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

NLRs join TLRs as innate sensors of pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Unleashing the therapeutic potential of NOD-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Humoral immune responses to a single allele PfAMA1 vaccine in healthy malaria-naïve adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Trial Watch: Experimental Toll-like receptor agonists for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Mycobacterium bovis bacillus Calmette-Guérin-induced macrophage cytotoxicity against bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Role of bacillus Calmette-Guérin in the treatment of advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Targeting Toll-like receptors: emerging therapeutics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

A human homologue of the Drosophila Toll protein signals activation of adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Signalling adaptors used by Toll-like receptors: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

When signaling pathways collide: positive and negative regulation of toll-like receptor signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Targeting TLRs expands the antibody repertoire in response to a malaria vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Toll-like receptor 4 signaling by follicular dendritic cells is pivotal for germinal center onset and affinity maturation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Use of defined TLR ligands as adjuvants within human vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

The role of inflammasomes in the immunostimulatory effects of particulate vaccine adjuvants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

MDP and other muropeptides--direct and synergistic effects on the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

TLR8 and NOD signaling synergistically induce the production of IL-1β and IL-23 in monocyte-derived DCs and enhance the expression of the feedback inhibitor SOCS2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Anthrax vaccine: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Insect cell-expressed hemagglutinin with CpG oligodeoxynucleotides plus alum as an adjuvant is a potential pandemic influenza vaccine candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Immunobiology of human cytomegalovirus: from bench to bedside.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Recombinant glycoprotein B vaccine formulation with Toll-like receptor 9 agonist and immune-stimulating complex induces specific immunity against multiple strains of cytomegalovirus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Hepatitis C virus soluble E2 in combination with QuilA and CpG ODN induces neutralizing antibodies in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Enhancement of humoral immunity in mice by coupling pUCpGs10 and aluminium to the HCV recombinant immunogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Protective immunity of pneumococcal glycoconjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Evaluation of vaccines for H5N1 influenza virus in ferrets reveals the potential for protective single-shot immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Mycobacterium tuberculosis and TLR2 agonists inhibit induction of type I IFN and class I MHC antigen cross processing by TLR9

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Skewed pattern of Toll-like receptor 4-mediated cytokine production in human neonatal blood: low LPS-induced IL-12p70 and high IL-10 persist throughout the first month of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Acquisition of adult-like TLR4 and TLR9 responses during the first year of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Dysregulation of human Toll-like receptor function in aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

Nod1-Mediated Innate Immune Recognition of Peptidoglycan Contributes to the Onset of Adaptive Immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811185

10.1586/14760584.2013.811185

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference